van de Ven L L, Franke C L, Koehler P J
E. Merck Nederland b.v. Amsterdam, The Netherlands.
Cephalalgia. 1997 Aug;17(5):596-9. doi: 10.1046/j.1468-2982.1997.1705596.x.
The objective of the present study was to assess the efficacy of bisoprolol in migraine prophylaxis. A double-blind placebo-controlled study was conducted in 226 patients with migraine with or without aura, a migraine history of at least 2 years at least 3 documented attacks during the 28 days run-in period. The duration of treatment was 12 weeks following an initial 28 days' run-in period. Patients reported the number of attacks and their severity in a diary. Treatment with bisoprolol 5 mg resulted in a significant reduction in the frequency of migraine attacks (39% vs 22%) compared to placebo treatment (p < 0.05). Treatment had no effect on the duration and severity of the attacks. Bisoprolol was well tolerated.
本研究的目的是评估比索洛尔预防偏头痛的疗效。对226例有或无先兆偏头痛患者进行了一项双盲安慰剂对照研究,这些患者偏头痛病史至少2年,在28天的导入期内至少有3次记录在案的发作。在最初28天的导入期后,治疗持续12周。患者在日记中记录发作次数及其严重程度。与安慰剂治疗相比,5 mg比索洛尔治疗使偏头痛发作频率显著降低(39%对22%)(p<0.05)。治疗对发作的持续时间和严重程度没有影响。比索洛尔耐受性良好。